References Introduced During IPR Proceeding Not Necessarily New Evidence to Which Patent Owner Had No Opportunity to Respond

May 23, 2018

Reading Time : 2 min

The IPR petition alleged that the claim would have been obvious in light of the combination of two references: Austin and Brehove. Austin teaches the use of oxaboroles as fungicides and discloses that tavaborole inhibits a variety of fungi, including C. albicans. Brehove teaches that use of similar types of compounds to treat onchomycosis and discloses the results of in vivo testing of two such compounds where a patient’s onchomycosis was successfully treated. The Board concluded that a person of ordinary skill in the art would have expected that tavaborole, which shares functional activity with the Brehove compounds against C. albicans, would also have functional activity against other fungi responsible for onchomycosis (like dermatophytes), and would have combined Austin with Brehove with a reasonable expectation of success.

In reaching its conclusion, the Board cited evidence from three additional articles: Nimura, Segal and Mertin. On appeal, Anacor argued that the Board improperly relied on Segal and Mertin, which was new evidence not cited in the petition and to which Anacor did not have an opportunity to respond. The Federal Circuit explained that there is “no blanket prohibition against the introduction of new evidence,” which is “to be expected” during an IPR proceeding, so long as the opposing party has notice and an opportunity to respond. Moreover, a petitioner may introduce new evidence in reply to the patent owner’s evidence, or to document “the knowledge that skilled artisans would bring to bear” in the analysis.

Here, Anacor had notice and several opportunities to respond to both references. Anacor spent three pages of its patent owner’s response discussing Segal. Mertin was the third article in a series of three. Anacor’s expert, Dr. Lane, relied on the first two Mertin articles in her declaration. When cross-examined about the third Mertin article, Dr. Lane admitted that she was familiar with it. The third Mertin article was used again at the deposition of another Anacor expert and was discussed extensively by Anacor at the hearing before the Board. The Federal Circuit concluded that “Anacor had ample notice of and an opportunity to respond to the Segal and Mertin references, which in any event were properly offered in reply to arguments made by Anacor and for the purpose of showing the state of the art at the time of the patent application.” Accordingly, Anacor had not been denied its procedural rights.

Anacor Pharms., Inc. v. Iancu, No. 17-1947 (Fed. Cir. May 14, 2018)

Share This Insight

Previous Entries

IP Newsflash

April 1, 2025

The District of Delaware recently denied in part a motion to compel production of documents and testimony between a patentee and potential investors, valuation firms and an international bank based on the common interest exception. In so doing, the court reaffirmed that disclosure of privileged information to third parties will generally waive privilege unless it can be shown that the parties’ interests are identical and the communications are legal, not solely commercial.

...

Read More

IP Newsflash

March 24, 2025

The Federal Circuit affirmed a Patent Trial and Appeal Board (PTAB) final written decision holding that the prior art exception of AIA Section 102(b)(2)(B) does not apply to a prior sale by an inventor when the sale is conducted in private. According to the Federal Circuit, a sale must disclose the relevant aspects of the invention to the public to qualify for the prior art exception of Section 102(b)(2)(B).

...

Read More

IP Newsflash

March 21, 2025

Under the Lanham Act, a plaintiff who prevails on a trademark infringement claim may be entitled to recover the “defendant’s profits” as damages. The Supreme Court in Dewberry Group, Inc. v. Dewberry Engineers Inc. unanimously construed “defendant’s profits” in 35 USC § 1117(a) to mean that only the named defendant’s profits can be awarded, not the profits of other related corporate entities. The Court, however, left open the possibility that other language in § 1117(a) may allow for damages linked to the profits of related entities, if properly raised and supported.

...

Read More

IP Newsflash

March 13, 2025

In a series of rulings on a motion in limine, the District of Delaware recently distinguished between what qualifies as being incorporated by reference and what does not for the purposes of an anticipation defense. In short, a parenthetical citation was held to be insufficient, while three passages discussing a cited reference met the test.

...

Read More

IP Newsflash

March 4, 2025

On February 28, 2025, the USPTO announced that it was rescinding former Director Vidal’s 2022 memorandum on discretionary denials by the Patent Trial and Appeal Board. The 2022 memorandum effectively narrowed the application of discretionary denials in cases with parallel district court litigation by specifying instances where discretionary denial could not be issued. With the withdrawal of the memorandum, individual PTAB panels will regain flexibility in weighing discretionary denials. While the long-term effect of that increased flexibility is not yet known, the immediate effect is likely to be a shift towards the discretionary analysis applied by PTAB panels before the issuance of the memorandum.

...

Read More

IP Newsflash

March 3, 2025

A District of Delaware judge recently granted a defendant’s motion to include a patent prosecution bar in its proposed protective order after determining that litigation counsel’s ability to practice before the Patent Office—without ever having represented the plaintiffs at the Patent Office in the past—weighed heavily in favor of the bar.

...

Read More

IP Newsflash

February 12, 2025

The Federal Circuit recently reversed a district court decision that found a patent that did not describe after-arising technology failed to satisfy the written description requirement. In so doing, the Federal Circuit explained that written description and enablement are evaluated based on the subject matter that is claimed, not the products that practice those claims. As a result, the patentee was not required to describe unclaimed, later-discovered features of the accused products despite the broad language in the claims that undisputedly covered the products.

...

Read More

IP Newsflash

January 24, 2025

The District of Delaware recently rejected a patentee’s argument that non-production of an opinion letter from counsel, combined with knowledge of the patent, warranted a finding that defendant induced infringement.

...

Read More

© 2025 Akin Gump Strauss Hauer & Feld LLP. All rights reserved. Attorney advertising. This document is distributed for informational use only; it does not constitute legal advice and should not be used as such. Prior results do not guarantee a similar outcome. Akin is the practicing name of Akin Gump LLP, a New York limited liability partnership authorized and regulated by the Solicitors Regulation Authority under number 267321. A list of the partners is available for inspection at Eighth Floor, Ten Bishops Square, London E1 6EG. For more information about Akin Gump LLP, Akin Gump Strauss Hauer & Feld LLP and other associated entities under which the Akin Gump network operates worldwide, please see our Legal Notices page.